6533b854fe1ef96bd12ae8e9
RESEARCH PRODUCT
LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Ming LeiMarcelo GarridoTomasz SkoczylasK. ShitaraKaoru KondoArinilda Campos BragagnoliT. LiuMarkus MoehlerC. GallardoLucjan WyrwiczMustapha TehfeYelena Y. JanjigianM. LiJaffer A. AjaniElena ElimovaKensei YamaguchiLiang ShenValerie Poulartsubject
Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentFirst lineEsophageal adenocarcinomaCancerIpilimumabHematologyAdvanced gastric cancerGastroesophageal Junctionmedicine.diseaseOncologyInternal medicinemedicineNivolumabbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2021-09-01 | Annals of Oncology |